Entering text into the input field will update the search result below

Astellas' phase 3 trial of fezolinetant to treat menopause symptoms meets main goal

Mar. 07, 2022 9:14 AM ETAstellas Pharma Inc. (ALPMY), ALPMFBy: Ravikash, SA News Editor

Doctor doing research in lab during COVID-19

Morsa Images/DigitalVision via Getty Images

  • Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) said fezolinetant met a main goal of a phase 3 trial evaluating the oral, nonhormonal compound to treat vasomotor symptoms associated with menopause.
  • VMS, commonly called hot flashes or flushes and night sweats are

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.